LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

Size: px
Start display at page:

Download "LubriTose Mannitol Michael Crowley, Director of R&D, Excipients"

Transcription

1 LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

2 Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY PH Taste & Nutrition

3 3 Taste & Nutrition

4 Science & Technology Expertise A robust foundation of technical expertise made up of integrated disciplines embedded in science, research and technology. Over 800 R&D Scientists 250+ w/ PhD s & MSc degrees Global infrastructure that is aligned through common information system architecture Expertise across a range of technical disciplines 4 Taste & Nutrition

5 Excipient Technologies Lactose Flavors Tabletting Systems Film Coatings Glycerides Portfolio Anhydrous Lactose Crystalline Monohydrate Spray Dried Monohydrate Inhalation Lactose Portfolio Flavor Modulator Technology (fmt ) Crystals Liquid & Powder Portfolio Lubricated Compression Aid Fast Disintegrating Orally Dissolving Portfolio (SheffCoat) Immediate Release Moisture Barrier Enteric Natural Portfolio Mono & Diglyceride Acetylated Monoglyceride Polysorbates Original patent for Anhydrous 25 different off-the-shelf grades Custom particle size engineering capabilities Batch to batch consistency Dual manufacturing sites Best in class flavor library with DMF s Bitterness masking of APIs Experience in supplying nutraceutical and pharma customers Co-processed systems All monograph compliant materials Free flowing, highly compressible with low dusting properties Higher efficiency coatings Alternative and cost effective Custom formulation development Matching of existing coating Tablet functionality testing Tablet hardness maintained Low ejection forces Dispersing Agent Animal Rennet Free 5 Taste & Nutrition

6 Kerry Lactose Over 70 year experience producing lactose Highlights Kerry (Sheffield) brands Anhydrous and crystalline Anhydrous DT brand Anhydrous DTHV brand Three manufacturing facilities Foremost Farms brands Spray dried and crystalline Fast Flo 316 brand Pharmaceutical Film Coatings SheffCoat brand SheffCel brand HPMC 6 Taste & Nutrition

7 Kerry Co-Processing Technology Technologies Co-spray drying Fluid bed agglomeration Hot melt extrusion Particle coating Functional co-processing philosophy Not just ingredient combination for ease of purchase or blending Manufacturing or process improvement Stability improvements Challenging API s Functional synergies 7 Taste & Nutrition

8 LubriTose Kerry developed Self Lubricating Excipients- LubriTose Coated with glyceryl monostearate Ejection forces similar as when using magnesium stearate Ease of use (no over blending and less dust) LubriTose Family LubriTose SD LubriTose AN LubriTose MCC LubriTose Mannitol 8 Taste & Nutrition

9 LubriTose LubriTose SD Spray dried Lactose 96% Glyceryl monostearate 4% LubriTose AN Anhydrous Lactose 96% Glyceryl monostearate 4% LubriTose MCC Microcrystalline cellulose 98% Glyceryl monostearate 2% LubriTose Mannitol Spray dried mannitol 96% Glyceryl monostearate 4% 9 Taste & Nutrition

10 LubriTose Mannitol Study Objective Objective: To compared LubriTose Mannitol to Spray Dried Mannitol and determine if there are benefits with LubriTose Mannitol Tablet lubrication comparison Compressibility comparison Tablet weight variability testing Tablet stability testing 10 Taste & Nutrition

11 Acknowledgment Study completed by St. John Fisher College Study lead: Vivek S. Dave, P.D. Assistant Professor (Pharmaceutical Sciences) St. John Fisher College Wegmans School of Pharmacy Rochester, NY 11 Taste & Nutrition

12 Materials LubriTose Mannitol Physical blends: SD Mannitol (brand 1)/MCC/Magnesium stearate SD Mannitol (brand 2)/MCC/Magnesium stearate NOTE: The LubriTose Mannitol samples were compressed neat, i.e. without adding anything. The other samples, i.e. the spray-dried mannitol could not be compacted successfully in their pure form due to extensive capping and lamination issues. For these materials, binary mixtures (1:1) with Avicel PH102 were prepared and lubricated with Mg-stearate (0.5% w/w, 2 minute blending). These mixtures were then compressed into compacts. 12 Taste & Nutrition

13 Methods Tablet Ejection Force Comparison Tablet ejection Tablet ejections were not measured during the SJF study. However, Kerry has performed extensive testing on the other LubriTose grades using an instrumented press. We have compared ejection forces for the LubriTose products to physical blends of the corresponding excipients with magnesium stearate. A curve of LubriTose AN is included. This is a simulated worst case scenario as anhydrous lactose would stick easily without proper lubrication. We would expect similar results when using LubriTose Mannitol. 13 Taste & Nutrition

14 Methods Compression Evaluations Tablet manufacture The tablets (compacts) of the samples were prepared on an instrumented, 10- station, single-layer, rotary tablet press (Model: Piccola B-506, SMI Inc., Lebanon, NJ) using 10mm, standard-concave, B tooling (SMI Inc., Lebanon, NJ). The target compact weight was set at 500 mg. The compacts were prepared at a constant tableting speed of 20RPM. The compacts were prepared at different compression forces ranging from 5-25KN, in 5 KN increments. Tablet compression The compacts were prepared at different compression forces ranging from 5-25KN, in 5 KN increments. The breaking force (diametrical crushing strength) of the prepared compacts was tested using the method specified in the USP38 NF33, general chapter <1217> on tablet breaking force. Briefly, 10 randomly selected tablets from each batch were tested using an automatic hardness tester (Model: VK200, Varian, Inc., Cary, NC). The compact breaking force is reported in Kp units. 14 Taste & Nutrition

15 Methods Weight and Stability Tablet weight evaluation The weight variation of the prepared compacts was evaluated using the method specified in the USP 38 NF 33, general chapter <905> on the uniformity of dosage units. Tablets (n=10) were randomly selected from each batch, and individually weighted on an electronic balance, and the weight recorded. Stability studies All samples (neat powders and the prepared compacts) were subjected to stability testing for a period of one month. The standard stability conditions, i.e. 25 C/60%RH, and 40 C/75% RH were used to assess the influence of temperature and humidity on the samples. The powder samples, and the prepared compacts were placed in open, 6 inch plastic weighing boats (for maximum exposure) in the stability chambers (Model: Forma TM 3911, Thermo Scientific, Rochester, NY). The powder and the compact samples were pulled out on day 10, day 20, and day 30). These samples were evaluated using the methods above, and compared to the day 0 samples. 15 Taste & Nutrition

16 Powder SEMs LubriTose Mannitol SD Mannitol 200x 1000x 5000x 16 Taste & Nutrition

17 Tablet SEMs 17 Taste & Nutrition

18 Tablet SEMs LubriTose Mannitol SD Mannitol 200x 1000x 5000x 18 Taste & Nutrition

19 Ejection Force (lbs) LubriTose Mannitol Lubrication Evaluation 21 Ejection force - LubriTose AN vs Lactose/Magnesium Stearate Compression Force (lbs) Lubritose AN DT 1% mag stear. Note: 1% Mg. Stearate not typical but used to provide excellent lubrication for comparative purposes 19 Taste & Nutrition

20 Lubritose Mannitol Compression Evaluation 350 Compression Comparison Compression Force vs Breaking Force Mannitol 1 + Avicel Mannitol 2 + Avicel 20 Taste & Nutrition

21 Lubritose Mannitol Compression Evaluation 350 Compression Comparison Compression Force vs Breaking Force Lubritose Mannitol Mannitol 1 + Avicel Mannitol 2 + Avicel 21 Taste & Nutrition

22 Tablet Weight Uniformity Lubritose Mannitol SD Mannitol: Avicel PH102 (1:1) SD mannitol 2: Avicel PH102 (1:1) Condition Compression force (KN) Day ± ± ± ± C/60% RH Day ± ± ± ± 1.03 Day ± ± ± ± C/75% RH Day ± ± ± ± 0.99 Day ± ± ± ± 1.23 Condition Compression force (KN) Day ± ± ± ± C/60% RH Day ± ± ± ± 2.32 Day ± ± ± ± C/75% RH Day ± ± ± ± 2.22 Day ± ± ± ± 4.73 Condition Compression force (KN) Day ± ± ± ± C/60% RH Day ± ± ± ± 2.62 Day ± ± ± ± C/75% RH Day ± ± ± ± 2.76 Day ± ± ± ± Taste & Nutrition

23 Tablet Stability SD Mannitol 1 23 Taste & Nutrition

24 Tablet Stability SD Mannitol 2 24 Taste & Nutrition

25 Tablet Stability LubriTose Mannitol 25 Taste & Nutrition

26 LubriTose Mannitol Study Objective - Recap Tablet lubrication comparison Compressibility comparison Tablet weight variability testing Tablet stability testing 26 Taste & Nutrition

27 Study Conclusions - Lubrication No tablet sticking was observed across all compression forces Low ejection forces across all compression forces Similar to physical blend with magnesium stearate at 1% 27 Taste & Nutrition

28 Study Conclusions Compression Comparison Able to achieved tablet breaking strength of 300kN Tablet capping was observed with SD Mannitol alone Required addition of MCC to SD Mannitol in order to eliminate capping and achieve breaking strength of 300kN Tablets were less porous than those with SD Mannitol 28 Taste & Nutrition

29 Study Conclusions Tablet Weight Variability Tablet weight variability was low across all compression forces tested (10kN -25kN) LubriTose Mannitol variability was ~+/- 1 mg for 500mg tablets SD Mannitol was ~ +/- 3 mg, with a high of 5.4 mg 29 Taste & Nutrition

30 Study Conclusions Stability Testing Tablets were produced and stored under accelerated stability conditions Breaking strength of tablets was measured after storage (0, 10, and 20 days) With LubriTose Mannitol, breaking strength dropped from ~300kN to ~250kN With SD Mannitol/MCC, strength dropped dramatically, from ~300kN to ~75kN 30 Taste & Nutrition

31 Notes and Next Steps Notes: Samples available from at least three commercial lots Fully commercialized process and DMF available Product currently used in market Next Steps: Perform studies of LubriTose Mannitol with some model APIs Evaluate LubriTose Mannitol at various use levels Thank you for your attention! 31 Taste & Nutrition

Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose

Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose 1 Pharmaceutical industry borrowed ingredients from other industries Food Cosmetic Industrial Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work that has all changed

More information

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants? Wettable Magnesium Stearate Presented By: Richard Pudlo P.E. Principal Chemical Engineer April 29 th, 2015 What Are Customers Looking for in Selecting Pharmaceutical Lubricants? Meet USP/.NF monograph

More information

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation METHOCEL Premium Cellulose Ethers Application Data The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation INTRODUCTION Hydrophilic matrices

More information

Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)

Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series) Technical Data Direct Compression Ranitidine Formulation Direct Compression Formulation Using Starch 15 with Ranitidine HCl (15 mg) Tablets, Film Coated with Opadry II (5F Series) INTRODUCTION Ranitidine

More information

The unlocked synergy of DFE Pharma MCC

The unlocked synergy of DFE Pharma MCC The unlocked synergy of DFE Pharma MCC We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients for oral solid dose and dry powder inhalation formulations.

More information

Technical brochure StarLac

Technical brochure StarLac T R TABLETING AC DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is

More information

FLORITER. New Technology for Innovative Formulation Design.

FLORITER. New Technology for Innovative Formulation Design. FLORITER New Technology for Innovative Formulation Design www.tomitaph.co.jp FLORITE Dramatically Change Your Formulation FLORITE is synthetic Calcium Silicate with exceptional liquid absorbency and excellent

More information

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System Opadry Enteric Application Data Acrylic-Based Coating System Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System INTRODUCTION Acetylsalicylic acid (aspirin)

More information

STARCH Application Data

STARCH Application Data STARCH 1500 Application Data Partially Pregelatinized Maize Starch Starch 1500, Partially Pregelatinized Maize Starch, Used as a Binder Disintegrant in High Shear Wet Granulation Comparison to Povidone

More information

Formulation and Evaluation

Formulation and Evaluation Chapter-5 Formulation and Evaluation 5.1 OBJECTIVE After successful taste masking and solubility enhancement of drugs in preliminary studies, by using Mannitol Solid Dispersion, next step includes the

More information

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100 IC OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE AC Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture

More information

SENTRY TM POLYOX Water Soluble Resins

SENTRY TM POLYOX Water Soluble Resins SENTRY TM POLYOX Water Soluble Resins Technical Information on Stability Introduction Key Points Antioxidants SENTRY POLYOX WSR resins consist of a family of high molecular weight polyethers with nominal

More information

Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets

Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets Technical Data Direct Compression Loratadine Formulation Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets INTRODUCTION Loratadine is a popular over-the-counter, nonsedating

More information

Primellose is an excellent choice as superdisintegrant in ODT applications

Primellose is an excellent choice as superdisintegrant in ODT applications Primellose is an excellent choice as superdisintegrant in ODT applications MCC Starch Lactose Inhalation Superdisintegrants Summary In orally disintegrating tablets, the excipients of choice in direct

More information

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies VIVAPHARM PVP/VA Copovidone, Ph.Eur. USP/NF, JPE, E 1208, FCC The Ultimate Tablet Binder for All Processing Technologies Direct Compression Dry Granulation Hot Melt Extrusion Wet Granulation VIVAPHARM

More information

Re-compaction properties of lactose and microcrystalline cellulose

Re-compaction properties of lactose and microcrystalline cellulose Re-compaction properties of lactose and microcrystalline cellulose Individual excipients MCC Starch Lactose Inhalation Superdisintegrants SuperTab 21AN (anhydrous lactose) is the preferred form of lactose

More information

Technical brochure CombiLac

Technical brochure CombiLac OM I AC TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is

More information

REVISION OF MONOGRAPH ON TABLETS. Tablets

REVISION OF MONOGRAPH ON TABLETS. Tablets March 2011 REVISION OF MONOGRAPH ON TABLETS Final text for addition to The International Pharmacopoeia This monograph was adopted by the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical

More information

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices METHOCEL Application Data Premium Cellulose Ethers The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices ABSTRACT SUMMARY This

More information

Content Uniformity of Direct Compression tablets

Content Uniformity of Direct Compression tablets Content Uniformity of Direct Compression tablets Contents 1 Summary 4 2 Introduction 4 3 The role of drug particle size 4 4 The role of mixing strategy 5 5 The role of excipients 5 6 Laboratory data 6

More information

Granulation Aggregation

Granulation Aggregation Granulation Aggregation Wet granulation Solvent granulation (crust granules) Binder granulation (sticked granules) Granulation liquid Water Water + alcohol mixture Macromolecular colloidal solution i.e.:

More information

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations TECHNICAL INFORMATION 1426 RxCIPIENTS FM 1 A versatile excipient for orally disintegrating tablet (ODT) formulations Table of contents 1 Introduction 3 2 Mode of action and advantages of RxCIPIENTS FM

More information

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium Available online on www.ijddt.com International Journal of Drug Delivery Technology 214; (3); 98-13 Research Article ISSN: 97 441 Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast

More information

Permeability Study on Cellulose Acetate Butyrate Coating Film

Permeability Study on Cellulose Acetate Butyrate Coating Film Permeability Study on Cellulose Acetate Butyrate Coating Film Please note: This article is the original unedited version of the article that was featured in Drug Delivery Technology, Vol. (8), NO. (2),

More information

SUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier

SUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier 9/17/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Aloe Vera (Powder) (Freeze Dried) 0.200 g Tacrolimus 5% Stock Powder Blend 0.600 g Ethoxy Diglycol 1.0 ml Medisca U-Mild

More information

CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION

CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION LEARNING OBJECTIVES The objectives of this unit are to: Understand the formulation of solid dosage form. Understand the characteristic

More information

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS Int. J. Chem. Sci.: 8(1), 2010, 405-414 STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS V. L. NARASAIAH, T. KARTHIK KUMAR, D. SRINIVAS, K. SOWMYA, P. L. PRAVALLIKA and Sk. Md. MOBEEN

More information

ORAL DOSAGE OVERVIEW

ORAL DOSAGE OVERVIEW ORAL DOSAGE OVERVIEW AN UNWAVERING COMMITMENT TO ENABLING LIFE-SAVING PHARMACEUTICALS The safety of your patients is your number one priority. That s why the quality and stability of your formulations

More information

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant EXCIPIENTS STARCH 1500 Proven and Trusted Excipient for Performance and Versatility Effective and economical disintegrant Excellent stability for moisture sensitive drugs Manufactured exclusively for the

More information

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy Dr. Philipp Hebestreit, an enabler in excipients Pharma Ingredients & Services. Welcome to more opportunities.

More information

Innovations in Design: NIA-West. Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017

Innovations in Design: NIA-West. Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017 Innovations in Design: NIA-West Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017 1 Innovations in Design: How Do You Stand Out? If all other competitors are the same

More information

LAB.2. Tablet Production Methods

LAB.2. Tablet Production Methods LAB.2 Tablet Production Methods Dry methods Direct compression Dry granulation Wet methods Wet granulation Regardless whether tablets are made by direct compression or granulation, the first step, milling

More information

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-8 Page 1 of 6 Are Cellulosic Controlled Release Technologies Vulnerable to Dose Dumping in Ethanolic Dissolution Media? Elanor Pinto,

More information

Excipient Considerations for Continuous Manufacturing Implementation

Excipient Considerations for Continuous Manufacturing Implementation Excipient Considerations for Continuous Manufacturing Implementation FDA-PQRI Conference March 22-24, 2017 David R. Schoneker Director of Global Regulatory Affairs Email: dschoneker@colorcon.com 1 Continuous

More information

Food supplement manufacture

Food supplement manufacture Food supplement manufacture Nick Bennett BSc. RNutr April 2018 1 Introduction There are many different product formats available Liquids, powders, tablets, capsules etc Many different types of machine

More information

A matter of timing. ensure optimal delivery for acid-sensitive products. capsugel.com

A matter of timing. ensure optimal delivery for acid-sensitive products. capsugel.com A matter of timing ensure optimal delivery for acid-sensitive products capsugel.com The preferred choice for you and your customers Capsugel DRcaps capsules offer nutritional supplement makers a dosage

More information

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency Pharma & Food Solutions POLYOX TM Water Soluble Resins Combining Flexibility with Consistency POLYOX 9-13 POLYOX 9-13 POLYOX * are nonionic poly (ethylene oxide) polymers that meet all the specifications

More information

The binding performance of DFE Pharma Starch

The binding performance of DFE Pharma Starch The binding performance of DFE Pharma Starch MCC Starch Lactose Inhalation Superdisintegrants We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients

More information

STUDY OF THE DETERIORATION OF ASPIRIN IN THE PRESENCE OF VARIOUS EXCIPIENTS

STUDY OF THE DETERIORATION OF ASPIRIN IN THE PRESENCE OF VARIOUS EXCIPIENTS STUDY OF THE DETERIORATION OF ASPIRIN IN THE PRESENCE OF VARIOUS EXCIPIENTS D.L.D.A.N DAHANAYAKA, A. MUNISINGHE, D.T.U. ABEYTUNGA DEPARTMENT OF CHEMISTRY, UNIVERSITY OF COLOMBO Abstract Aspirin is a non

More information

Adopting Technologies to Enhance Quality in Manufacturing

Adopting Technologies to Enhance Quality in Manufacturing Adopting Technologies to Enhance Quality in Manufacturing Sandip B. Tiwari, Ph.D. March 18, 2012 Current Status of Quality in Pharma Manufacturing Pharmaceutical manufacturing techniques lag behind those

More information

Available online Research Article

Available online   Research Article Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 26, 8(2):7-7 Research Article ISSN : 975-7384 CODEN(USA) : JCPRC5 Optimization of directly compressible mixtures of microcrystalline

More information

CHEWABLE SOFTGEL TECHNOLOGY

CHEWABLE SOFTGEL TECHNOLOGY CHEWABLE SOFTGEL TECHNOLOGY PROCAPS AT A GLANCE Procaps is a Pharmaceutical Group dedicated to delivering innovation, health and Nutrition. We work hand in hand with our customers and develop products

More information

Challenges and solutions for moisture sensitive API formulation

Challenges and solutions for moisture sensitive API formulation Challenges and solutions for moisture sensitive API formulation Introduction Today, formulators are looking for alternative processes to reformulate existing products or to formulate New Chemical Entities

More information

Folic Acid in Human Nutrition

Folic Acid in Human Nutrition Folic Acid in Human Nutrition Folic acid is a water soluble B vitamin widely distributed in foods. Deficiencies lead to impaired cell division and altered protein synthesis. Newborn children of women receiving

More information

Short Communication. Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L. J. TIROP AND K. A. M.

Short Communication. Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L. J. TIROP AND K. A. M. 61 East and Central African Journal of Pharmaceutical Sciences Vol. 18 (2015) 61-66 Short Communication Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L.

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article FORMULATION DEVELOPMENT AND EVALUATION OF IMMEDIATE RELEASE BILAYER TABLETS OF TELMISERTAN AND HYDROCHLOROTHIAZIDE

More information

Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier 7/12/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Tramadol Hydrochloride, EP 0.300 g Stevia Powder 0.15 g Glycerin, USP** 3.0 ml Beef Flavor (Powder) 2.00 g Chew-A-Treat

More information

US A United States Patent (19) 11 Patent Number: 5,635,209 Groenewoud et al. 45 Date of Patent: Jun. 3, 1997

US A United States Patent (19) 11 Patent Number: 5,635,209 Groenewoud et al. 45 Date of Patent: Jun. 3, 1997 US005635209A United States Patent (19) 11 Patent Number: Groenewoud et al. 45 Date of Patent: Jun. 3, 1997 (54) STABILIZED COMPOSITION OF LEVOTHYROXNE SODIUM MEDICATION 4,585,652 4,818,531 4/1986 Miller

More information

EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients

EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER Life-saving pharmaceuticals start with high-quality ingredients CONFIDENCE STRAIGHT FROM THE SOURCE From oral dosage excipients (Rx, Gx, nutraceuticals

More information

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009 Co-Processed Excipients: Regulatory Challenges Carl Mroz Colorcon Limited June 2009 What is a Co-Processed excipient? Several types of excipient contain multiple components by design Use of processing

More information

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical Excipient Quality & Trouble Shooting By Seema Trivedi GM, Technical Back Ground The Society for Pharmaceutical Dissolution Science (SPDS) had held its 6th Annual International Convention Disso India -

More information

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier 11/23/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Methimazole, USP 0.300 g Tuna Flavor 1.50 g Glycerin, USP** 6.0 ml Chew-A-Treat Compound A 22.80 g Chew-A-Treat Compound

More information

EP B1 (19) (11) EP B1 (12) EUROPEAN PATENT SPECIFICATION

EP B1 (19) (11) EP B1 (12) EUROPEAN PATENT SPECIFICATION (19) (11) EP 1 864 677 B1 (12) EUROPEAN PATENT SPECIFICATION (4) Date of publication and mention of the grant of the patent: 02.01.08 Bulletin 08/01 (1) Int Cl.: A61K 38/ (06.01) A61K 9/ (06.01) A61K 31/39

More information

SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING

SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING Dr. Dieter Lubda MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany Agenda: Sustained release

More information

Designed and manufactured specifically for pharmaceutical capsule filling

Designed and manufactured specifically for pharmaceutical capsule filling EXCIPIENTS Designed and manufactured specifically for pharmaceutical capsule filling Simple formulation Superior flow and weight uniformity Clean and efficient processing This document is valid at the

More information

CAPMUL + CAPTEX + ACCONON = SEDDS

CAPMUL + CAPTEX + ACCONON = SEDDS OUR SOLUTIONS PORTFOLIO ABITEC products are specifically designed for meeting the solubility challenges of the pharmaceutical industry. Our products can be used alone or in conjunction with one another

More information

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS International Journal of PharmTech Research CODEN( USA): IJPRIF ISSN : 0974-4304 Vol.1, No.3, pp 634-638, July-Sept 2009 FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS K. Reeta Vijaya

More information

YOUR ORAL SOLID DOSE. In pursuit of excipient excellence

YOUR ORAL SOLID DOSE. In pursuit of excipient excellence YOUR ORAL SOLID DOSE DFE Pharma globally supplies a unique, broad portfolio of key excipients including lactose, MCC, superdisintegrants and starches. Innovative products such as SuperTab 24AN and SuperTab

More information

SCIENTIFIC DISCUSSION. Efavirenz

SCIENTIFIC DISCUSSION. Efavirenz SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

More information

Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig

Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-069-1 (Supersedes PTR-069) Page 1 of 8 Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems

More information

Formulation and Evaluation of Amlodipine besylate orally disintegrating tablet

Formulation and Evaluation of Amlodipine besylate orally disintegrating tablet Indo American Journal of Pharmaceutical Research. 2011:2(1);146-12. ISSN NO. 2231-6876 Journal home page: http://www.iajpr.com/index.php/en/ INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH Formulation

More information

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/42

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/42 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 8 36 A1 (43) Date of publication: 14..09 Bulletin 09/42 (21) Application number: 084239.1 (1) Int Cl.: A61K 9/16 (06.01) A61K 9/ (06.01) A61K 31/4178 (06.01)

More information

A. General Appearance

A. General Appearance TABLET EVALUATION To design tablets and later monitor tablet production quality, quantitative evaluations and assessments of a tablet s chemical, physical, and bioavailability properties must be made.

More information

Narrowing the gap between clinical capsule formulations and commercial film-coated tablets

Narrowing the gap between clinical capsule formulations and commercial film-coated tablets Narrowing the gap between clinical capsule formulations and commercial film-coated tablets Based on formulation simplicity and blinding capability, hard gelatin capsules are preferrable compared with other

More information

Pharma Ingredients & Services. Ibuprofen. Technical Information. = Registered trademark of BASF group USP, Ph. Eur., JP

Pharma Ingredients & Services. Ibuprofen. Technical Information. = Registered trademark of BASF group USP, Ph. Eur., JP Technical Information Ibuprofen April 2010 Supersedes issue dated January 2010 03_030720e-10/Page 1 of 14 = Registered trademark of BASF group USP, Ph. Eur., JP Pharma Ingredients & Services 03_030720e-10

More information

Ingredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation 8/16/2018; Page 1 SUGGESTED FORMULATION Acyclovir, USP Ingredient Listing Qty. Unit NDC # Supplier Mineral Oil (Light), NF 3.0 ml Polyox TM WSR-301 Oral Adhesive Paste* *Formula # F 006 397 available on

More information

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) This document should not be treated as a comprehensive guideline; it serves as a

More information

Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products

Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products 57. Starch Convention, Detmold, April 26-28, 2006 K.-J. Steffens Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products Starches, Pharmaceutical Applications _ Starches

More information

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy Starch 1500 Application Data Partially Pregelatinized Maize Starch Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy OBJECTIVE To characterize

More information

Challenges in Developing Stable and Efficient Probiotic Formulations

Challenges in Developing Stable and Efficient Probiotic Formulations Challenges in Developing Stable and Efficient Probiotic Formulations Morgan Laloux morgan.laloux@capsugel.com +32 491 73 20 53 Summary Challenges in Formulating Probiotics Formulating Probiotics in Capsules

More information

DRY SYRUPS SWAPNA.M. Ist semester DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY, WARANGAL SEMINAR BY

DRY SYRUPS SWAPNA.M. Ist semester DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY, WARANGAL SEMINAR BY DRY SYRUPS SEMINAR BY SWAPNA.M M.PHARMACY Ist semester DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY, WARANGAL CONTENTS DEFINITION CHARACTERISTICS OF SUSPENSIONS

More information

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation 4/23/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Nifedipine, USP 0.975 g Silica Gel (Micronized) 0.75 g Medisca SPG Supposi-Base 189.06 g SPECIAL PREPARATORY CONSIDERATIONS

More information

Table 1. Coating Parameters

Table 1. Coating Parameters ACRYL-EZE Aqueous Acrylic Enteric System Application Data Performance Characteristics of Acryl-EZE, Aqueous Acrylic Enteric System Eudragit L1-55 is a copolymer of methacrylic acid and ethyl acrylate (1:1

More information

Formulation and evaluation of sublingual tablets of lisinopril

Formulation and evaluation of sublingual tablets of lisinopril Journal of GROVER Scientific & Industrial AGARWAL: Research FORMULATION AND EVALUATION OF SUBLINGUAL TABLETS OF LISINOPRIL Vol. 71, June 2012, pp. 413-417 413 Formulation and evaluation of sublingual tablets

More information

Easy, fast and reliable!

Easy, fast and reliable! Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. Tailormade formulated. s film coating products are one-step coating

More information

(12) Patent Application Publication (10) Pub. No.: US 2003/ A1

(12) Patent Application Publication (10) Pub. No.: US 2003/ A1 US 2003.01.18647A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0118647 A1 Seth (43) Pub. Date: (54) EXTENDED RELEASE TABLET OF Publication Classification METFORMIN (51)

More information

Formulation and Evaluation of Rosuvastatin Immediate Release Tablets 10 Mg

Formulation and Evaluation of Rosuvastatin Immediate Release Tablets 10 Mg IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:2319-7676. Volume 11, Issue 5 Ver. III (Sep. - Oct.2016), PP 01-05 www.iosrjournals.org Formulation and Evaluation

More information

The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder

The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder Hiroto Miyamoto KNOWKATSU 1 Abstract Cellulose and saccharide are commonly used filler-binder. This summary

More information

Karnataka Department of Pharmaceutical Technology, H.K.E. Society s College of Pharmacy, Gulbarga, Karnataka ABSTRACT KEYWORDS:

Karnataka Department of Pharmaceutical Technology, H.K.E. Society s College of Pharmacy, Gulbarga, Karnataka ABSTRACT KEYWORDS: 335 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 4(6): November-December 2015 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY

More information

Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015

Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015 Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015 Dr. Susanne Keitel Director EDQM, Council of Europe Outline 1. The European Pharmacopoeia 2. The importance of

More information

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process Direct With the right ingredients it s a simple, cost-effective manufacturing process TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow Speed and savings sounds good to us

More information

The Future of Co-processed Excipients

The Future of Co-processed Excipients The Future of Co-processed Excipients Dave Schoneker/Brian Carlin 6 May 2010 The Future of Co-processed Excipients Overview Definition of Coprocessed Excipients Regulatory aspects of Coprocessing Technological

More information

(51) Int Cl.: A61K 9/20 ( ) A61K 31/41 ( )

(51) Int Cl.: A61K 9/20 ( ) A61K 31/41 ( ) (19) TEPZZ 94677_A_T (11) (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 2.11.1 Bulletin 1/48 (1) Int Cl.: A61K 9/ (06.01) A61K 31/41 (06.01) (21) Application number: 116790.3 (22) Date of

More information

905 UNIFORMITY OF DOSAGE UNITS

905 UNIFORMITY OF DOSAGE UNITS Change to read: 905 UNIFORMITY OF DOSAGE UNITS [ NOTE In this chapter, unit and dosage unit are synonymous. ] To ensure the consistency of dosage units, each unit in a batch should have a drug substance

More information

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats)

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats) 4/11/2015; Page 1 Note: Fluoxetine Hydrochloride 5.6 mg is equivalent to Fluoxetine 5 mg. SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Fluoxetine Hydrochloride, USP 0.336 g Glycerin

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research J. Chem. Pharm. Res., 2010, 2(5):534-540 ISSN No: 0975-7384 CODEN(USA): JCPRC5 Formulation and evaluation of Valsartan film

More information

This certification is valid through 08/31/2011 Rabbi Menachem Genack, Rabbinic Administrator, CEO Page 1 of 6

This certification is valid through 08/31/2011 Rabbi Menachem Genack, Rabbinic Administrator, CEO Page 1 of 6 This is to certify that the following product(s) prepared by, 158 State Highway, Norwich, NY 13815 at the following facilitie(s) are under the supervision of the Kashruth Kerry Bio-Science-Norwich, Norwich,

More information

Office europeen des brevets. Publication number: Applicant: Chugai Seiyaku Kabushiki Kaisha 5-1, 5-chome, Ukima Kita-ku Tokyo(JP)

Office europeen des brevets. Publication number: Applicant: Chugai Seiyaku Kabushiki Kaisha 5-1, 5-chome, Ukima Kita-ku Tokyo(JP) J Europaisches Patentamt European Patent Office Publication number: 0 2 932 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION Application number: 87100549.2 Date of filing: 16.01.87 int. Ci.

More information

COMPARATIVE EFFECT OF DIFFERENT HIGH FUNCTIONALITY EXCIPIENTS ON VARIOUS CHARACTERISTICS OF VARDENAFIL HCL TABLETS (BCS II DRUG)

COMPARATIVE EFFECT OF DIFFERENT HIGH FUNCTIONALITY EXCIPIENTS ON VARIOUS CHARACTERISTICS OF VARDENAFIL HCL TABLETS (BCS II DRUG) IJPSR (2014), Vol. 5, Issue 12 (Research Article) Received on 27 April, 2014; received in revised form, 28 July, 2014; accepted, 08 August, 2014; published 01 December, 2014 COMPARATIVE EFFECT OF DIFFERENT

More information

Figure 1: SEM Mannogem EZ (1000x)

Figure 1: SEM Mannogem EZ (1000x) Carrier-Mixing of Mannogem EZ with Micronized Low dose Furosemide: Uniformity of dosage unit study Sunil Kumar N *, John K Tillotson, Praveen Saligram, Robert Duffy SPI Pharma Inc. Introduction: To produce

More information

The purpose of this research work was to develop a stable formulation of Antihypertensive drugs of the

The purpose of this research work was to develop a stable formulation of Antihypertensive drugs of the ISSN: 0975-766X CODEN: IJPTFI Available Online through Research Article www.ijptonline.com BILAYER TABLET: A NOVEL APPROACH FOR IMMEDIATE RELEASE OF TELMISARTAN AND HYDROCHLORTHAIZIDE COMBINATION. M S

More information

Formulation Facilitation of Powder Blends, Sugar-Free Coatings and HME with an Unique Polyol

Formulation Facilitation of Powder Blends, Sugar-Free Coatings and HME with an Unique Polyol Formulation Facilitation of Powder Blends, Sugar-Free Coatings and HME with an Unique Polyol Presented by Bodo Fritzsching, BENEO-Palatinit GmbH at Excipient Fest Americas May 5th, 2010 The Ritz Carlton,

More information

Volume: I: Issue-2: Aug-Oct ISSN NOVEL APPROACH IN FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF ONDANSETRON HYDROCHLORIDE

Volume: I: Issue-2: Aug-Oct ISSN NOVEL APPROACH IN FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF ONDANSETRON HYDROCHLORIDE Volume: I: Issue-2: Aug-Oct -2010 ISSN 0976-4550 NOVEL APPROACH IN FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF ONDANSETRON HYDROCHLORIDE * Hindustan Abdul Ahad, Anuradha CM, Chitta Suresh

More information

SUMMARY AND CONCLUSION

SUMMARY AND CONCLUSION SUMMARY AND CONCLUSION 8 SUMMARY AND CONCLUSIONS In spite of the many challenges faced by researchers while designing an effective, reproducible and stable dosage form, oral dosage forms continued to maintain

More information

Hydrocortisone 2%, Hydroquinone 6%, Kojic Acid 4%, Salicylic Acid 4%, Tretinoin 0.01% Topical Gel (Suspension, 20 g)

Hydrocortisone 2%, Hydroquinone 6%, Kojic Acid 4%, Salicylic Acid 4%, Tretinoin 0.01% Topical Gel (Suspension, 20 g) 8/22/2016; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Tretinoin 2% Stock Solution 0.10 ml Hydrocortisone (Micronized), USP 0.400 g Hydroquinone, USP 1.200 g Kojic Acid 0.800

More information

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml 12/20/2018; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier, USP 10 MU Sucrose, NF 23.00 g Propylene Glycol, USP 7.0 ml Medisca Oral Mix (Flavored Suspending Vehicle) 50.0 ml Medisca

More information

Preformulation Study. CHAPTER 3 Preformulation Study. 3.0 Introduction

Preformulation Study. CHAPTER 3 Preformulation Study. 3.0 Introduction CHAPTER 3 3.0 Introduction As per Sir Arthur Conan Doyle, It is a capital mistake to theorize before one has data. Preformulation work is the foundation for development of any robust formulations (G. Banker

More information

Pharmaceutical Studies on Formulation and Evaluation of Sustained Release Tablets Containing Certain Drugs

Pharmaceutical Studies on Formulation and Evaluation of Sustained Release Tablets Containing Certain Drugs Mansoura University Faculty of Pharmacy Department of Pharmaceutics Pharmaceutical Studies on Formulation and Evaluation of Sustained Release Tablets Containing Certain Drugs Thesis presented by Ali Saeed

More information

Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier 3/4/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Lidocaine, USP 3.000 g Prilocaine, USP 3.000 g Tetracaine, USP 1.200 g Stevia Powder 0.10 g Butylated Hydroxytoluene (BHT),

More information